Securities code: 000950 securities abbreviation: C.Q.Pharmaceutical Holding Co.Ltd(000950) Announcement No.: 2022-005 C.Q.Pharmaceutical Holding Co.Ltd(000950)
With regard to the announcement that more than half of the shares of more than 5% shareholders are planned to be reduced, the person acting in concert of more than 5% shareholders of the company Maoye Commercial Co.Ltd(600828) guarantees that the information provided to the company is true, accurate and complete without false records, misleading statements or major omissions.
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
C.Q.Pharmaceutical Holding Co.Ltd(000950) (hereinafter referred to as “the company”) disclosed the pre disclosure announcement on the reduction plan of shareholders holding more than 5% (Announcement No.: 2021-095) on November 12, 2021, The person acting in concert Maoye Commercial Co.Ltd(600828) (hereinafter referred to as ” Maoye Commercial Co.Ltd(600828) “) of Shenzhen Maoye (Group) Co., Ltd. (hereinafter referred to as “Shenzhen Maoye”), a shareholder holding more than 5% of the company’s shares, plans to reduce no more than 52301020 shares of the company (accounting for 3% of the company’s total share capital) by means of centralized bidding or block trading within 3 months after 15 trading days from the date of disclosure of the announcement.
After the market closed on January 18, 2022, the company received Maoye Commercial Co.Ltd(600828) notification letter on the progress of reducing C.Q.Pharmaceutical Holding Co.Ltd(000950) shares, and learned that more than half of the reduction plan of Maoye Commercial Co.Ltd(600828) was January 18, 2022. According to several provisions on reducing shares of shareholders, directors, supervisors and senior managers of listed companies According to the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of Listed Companies in Shenzhen Stock Exchange, the implementation progress of the share reduction plan of Maoye Commercial Co.Ltd(600828) is hereby announced as follows:
1、 Shareholder reduction
1. Share reduction by shareholders
As of the disclosure date of this announcement, shareholders Maoye Commercial Co.Ltd(600828) have reduced 17416800 shares of the company during the reduction period of the share reduction plan, as follows:
Name of shareholder reduction method average price of reduction during reduction proportion of reduction of shares (yuan) (10000 shares)
Centralized bidding transaction from December 6, 2021 to 4.76 1741.6800 1% December 17, 2021
Block transaction – Maoye Commercial Co.Ltd(600828)
Other methods —-
Total from December 6, 2021 to 4.76 1741.6800 1% December 17, 2021
The share reduction of Maoye Commercial Co.Ltd(600828) comes from its participation in the company’s major asset sales and issuance of shares in 2017, the purchase of assets and related party transactions, and its acquisition of 73327536 non-public shares of the company. The price range during the reduction period is 4.73 yuan / share -4.82 yuan / share.
Maoye Commercial Co.Ltd(600828) and its concerted action person, Shenzhen Maoye, have reduced a total of 51756438 shares of the company, accounting for about 2.97% of the total share capital of the company since the previous disclosure of the simplified report on changes in equity (for details, see the relevant announcement disclosed by C.Q.Pharmaceutical Holding Co.Ltd(000950) on cninfo.com on November 25, 2016).
2. Shareholding of shareholders before and after this reduction
Shares held by shareholders before this reduction and shares held after this reduction
Name nature of shares proportion of shares in total share capital proportion of shares in total share capital (10000 shares) (10000 shares)
Total shares held 5589.7898 3.21% 3848.1098 2.21% Maoye, including shares with unlimited sales conditions
Commercial 5589.7898 3.21% 3848.1098 2.21% shares with limited sales conditions —-
2、 Other relevant instructions
1. Maoye Commercial Co.Ltd(600828) this reduction does not violate the relevant provisions of laws and regulations such as the securities law, the measures for the administration of the acquisition of listed companies, and the detailed rules for the implementation of share reduction by shareholders, directors, supervisors and senior managers of Listed Companies in Shenzhen Stock Exchange.
2. Maoye Commercial Co.Ltd(600828) the share reduction has been pre disclosed in accordance with relevant regulations. As of the date of this announcement, the number of shares actually reduced has not exceeded the number of shares planned to be reduced, and the reduction plan has not been implemented yet. 3. Maoye Commercial Co.Ltd(600828) this reduction will not affect the company’s governance structure or change the company’s control.
4. During the implementation of the reduction plan, Maoye Commercial Co.Ltd(600828) implements the reduction plan and performs the obligation of information disclosure in accordance with relevant regulations and requirements.
3、 Documents for future reference
Maoye Commercial Co.Ltd(600828) notification letter on the progress of reducing C.Q.Pharmaceutical Holding Co.Ltd(000950) shares
C.Q.Pharmaceutical Holding Co.Ltd(000950) board of directors January 19, 2022
